High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer.

ABSTRACT:

Objective

The aim of this study was to determine the efficacy and toxicity of oral administration of tegafur-uracil (UFT) at a high dose, 600 mg/day, based on the tegafur dose, against uterine cervical cancer.

Methods

This study consisted of a retrospective analysis. From April 1986 to March 1997, 309 patients with uterine cervical cancer were registered. Oral UFT was administered to 162 patients for maintenance therapy after an initial treatment (the UFT group). The other 147 patients were not treated with UFT (the control group). The survival rate was calculated for both groups and statistically analyzed using the log-rank test. Adverse events were compared between the UFT and control groups.

Results

In the UFT group, 103 patients (63.6%) received UFT for ≥90 days.

SUBMITTER: Sakaguchi I 

PROVIDER: S-EPMC4510335 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature